 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies Company NYSE: SQZ, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV demonstrating that the investigational cell therapy is safe and well-tolerated and can stimulate immune responses in certain patients with advanced or metastatic Human Papillomavirus positive HPV16 tumors. The trial also showed that the compa 